These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29357745)

  • 1. Targeting HER2 in Nuclear Medicine for Imaging and Therapy.
    Massicano AVF; Marquez-Nostra BV; Lapi SE
    Mol Imaging; 2018; 17():1536012117745386. PubMed ID: 29357745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Epidermal Growth Factor Receptor 2-Targeting [
    Alhuseinalkhudhur A; Lindman H; Liss P; Sundin T; Frejd FY; Hartman J; Iyer V; Feldwisch J; Lubberink M; Rönnlund C; Tolmachev V; Velikyan I; Sörensen J
    J Nucl Med; 2023 Sep; 64(9):1364-1370. PubMed ID: 37442602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides.
    Ge S; Li J; Yu Y; Chen Z; Yang Y; Zhu L; Sang S; Deng S
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
    Okarvi SM; AlJammaz I
    Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.
    Sörensen J; Velikyan I; Sandberg D; Wennborg A; Feldwisch J; Tolmachev V; Orlova A; Sandström M; Lubberink M; Olofsson H; Carlsson J; Lindman H
    Theranostics; 2016; 6(2):262-71. PubMed ID: 26877784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.
    Sörensen J; Sandberg D; Sandström M; Wennborg A; Feldwisch J; Tolmachev V; Åström G; Lubberink M; Garske-Román U; Carlsson J; Lindman H
    J Nucl Med; 2014 May; 55(5):730-5. PubMed ID: 24665085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer.
    Tolmachev V; Orlova A; Sörensen J
    Semin Cancer Biol; 2021 Jul; 72():185-197. PubMed ID: 33465471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular probes targeting HER2 PET/CT and their application in advanced breast cancer.
    Gao F; Liu F; Wang J; Bi J; Zhai L; Li D
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):118. PubMed ID: 38466436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a
    Zhao L; Liu C; Xing Y; He J; O'Doherty J; Huang W; Zhao J
    Mol Pharm; 2021 Sep; 18(9):3616-3622. PubMed ID: 34328338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
    Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
    J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
    Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
    J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
    Ulaner GA; Hyman DM; Lyashchenko SK; Lewis JS; Carrasquillo JA
    Clin Nucl Med; 2017 Dec; 42(12):912-917. PubMed ID: 28872549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2.
    Gebhart G; Flamen P; De Vries EG; Jhaveri K; Wimana Z
    J Nucl Med; 2016 Feb; 57 Suppl 1():81S-8S. PubMed ID: 26834107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
    Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
    J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy.
    Capala J; Bouchelouche K
    Curr Opin Oncol; 2010 Nov; 22(6):559-66. PubMed ID: 20842031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide Based Imaging Agents for HER2 Imaging in Oncology.
    Ducharme M; Lapi SE
    Mol Imaging; 2020; 19():1536012120960258. PubMed ID: 32957830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer
    Shi J; Du S; Wang R; Gao H; Luo Q; Hou G; Zhou Y; Zhu Z; Wang F
    J Transl Med; 2023 Jan; 21(1):19. PubMed ID: 36631812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.
    Henry KE; Ulaner GA; Lewis JS
    PET Clin; 2017 Jul; 12(3):269-288. PubMed ID: 28576166
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.